Efficacy
The combination of docetaxel, carboplatin, trastuzumab plus pertuzumab demonstrated a pathological complete response (pCR) rate of 66.2%, compared with 61.6% for Arm A and 57.3% for Arm B. The combination of trastuzumab and pertuzumab given concurrently or sequentially with an anthracycline-based, or concurrently with a carboplatin-based chemotherapy regimen, resulted in a low incidence of symptomatic left ventricular systolic dysfunction.r
Pathological complete response in the intention-to-treat populationr
© Ann Oncol 2013
A summary of the evidence supporting the effect of this protocol is below:
Outcome |
TRYPHAENA 2013r |
KRISTINE TRIO-021 2018r |
pCR (ypT0/is, ypN0) (%) |
66.2 |
55.7 |
Rate of breast conserving surgery for those whom mastectomy was planned (%) |
27 |
70 |
3-year disease-free survival results were 87% for group A, 88% for group B and 90% for group C. 3-year progression-free survival rates were 89% for group A, 89% for group B and 87% for group C. 3-year overall survival results were 94% for group A, 94% for group B and 93% for group C.r
Patients achieving a pCR were more likely to be disease free at 3 years (HR=0.27, 95% CI, 0.11 to 0.64).
Disease free survival (A), progression free survival (B) and overall survival (C)r
© Eur J Cancer 2018